Nalaganje...
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
Type 2 diabetes (T2D) is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions. In a recent cardiovascular outcomes trial, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG...
Shranjeno v:
| izdano v: | Eur Endocrinol |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Touch Medical Media
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5954590/ https://ncbi.nlm.nih.gov/pubmed/29922347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2018.14.1.17 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|